

Resource Summary Report

Generated by [RRID](#) on Jul 28, 2026

PerCP/Cyanine5.5 anti-human CD38

RRID:AB_2562183

Type: Antibody

Proper Citation

BioLegend Cat# 356614, RRID:AB_2562183

Antibody Information

URL: http://antibodyregistry.org/AB_2562183

Proper Citation: BioLegend Cat# 356614, RRID:AB_2562183

Target Antigen: CD38

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PerCP/Cyanine5.5 anti-human CD38

Description: This monoclonal targets CD38

Target Organism: human

Clone ID: Clone HB-7

Antibody ID: AB_2562183

Vendor: BioLegend

Catalog Number: 356614

Alternative Catalog Numbers: 356613

Record Creation Time: 20250820T023854+0000

Record Last Update: 20250820T140841+0000

Ratings and Alerts

No rating or validation information has been found for PerCP/Cyanine5.5 anti-human CD38.

No alerts have been found for PerCP/Cyanine5.5 anti-human CD38.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 8 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Conti A, et al. (2025) Senescence and inflammation are unintended adverse consequences of CRISPR-Cas9/AAV6-mediated gene editing in hematopoietic stem cells. *Cell reports. Medicine*, 6(6), 102157.

Hosking MP, et al. (2025) Preferential tumor targeting of HER2 by iPSC-derived CAR T cells engineered to overcome multiple barriers to solid tumor efficacy. *Cell stem cell*, 32(7), 1087.

Zhou C, et al. (2024) Nynrin preserves hematopoietic stem cell function by inhibiting the mitochondrial permeability transition pore opening. *Cell stem cell*, 31(9), 1359.

Della Volpe L, et al. (2024) A p38 MAPK-ROS axis fuels proliferation stress and DNA damage during CRISPR-Cas9 gene editing in hematopoietic stem and progenitor cells. *Cell reports. Medicine*, 5(11), 101823.

Ferrari S, et al. (2022) Choice of template delivery mitigates the genotoxic risk and adverse impact of editing in human hematopoietic stem cells. *Cell stem cell*, 29(10), 1428.

Omer-Javed A, et al. (2022) Mobilization-based chemotherapy-free engraftment of gene-edited human hematopoietic stem cells. *Cell*, 185(13), 2248.

Zhou R, et al. (2020) Acute SARS-CoV-2 Infection Impairs Dendritic Cell and T Cell Responses. *Immunity*, 53(4), 864.

Petrillo C, et al. (2018) Cyclosporine H Overcomes Innate Immune Restrictions to Improve Lentiviral Transduction and Gene Editing In Human Hematopoietic Stem Cells. *Cell stem cell*, 23(6), 820.